Development of Antibody-Based Therapeutics 2012
DOI: 10.1007/978-1-4419-5955-3_4
|View full text |Cite
|
Sign up to set email alerts
|

Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics

Abstract: The evolution of therapeutic antibodies has encompassed multiple engineering efforts in the hope of improving the efficacy, safety, and duration of effects of antibody-based drugs. Advances in protein engineering technologies afforded investigators the ability to overcome problems associated with introducing foreign antibodies into humans. These efforts included antibody chimerization, humanization, and the more recent development of human antibodies, all of which reduced anti-drug immune responses. Additional… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0
1

Year Published

2015
2015
2022
2022

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 153 publications
(168 reference statements)
0
2
0
1
Order By: Relevance
“…The expansion of therapeutic antibodies is a dynamic field that evolves alongside with technological developments. Advances in antibody engineering allowed to overcome the main problems associated with the immune response developed against foreign antibodies introduced into humans [ 137 ]. Antibody chimerization, humanization and the development of human antibodies were the major strategies adopted to reduce immunogenicity [ 68 ].…”
Section: Therapeutic Antibodies Against Tn and Stn Antigensmentioning
confidence: 99%
See 1 more Smart Citation
“…The expansion of therapeutic antibodies is a dynamic field that evolves alongside with technological developments. Advances in antibody engineering allowed to overcome the main problems associated with the immune response developed against foreign antibodies introduced into humans [ 137 ]. Antibody chimerization, humanization and the development of human antibodies were the major strategies adopted to reduce immunogenicity [ 68 ].…”
Section: Therapeutic Antibodies Against Tn and Stn Antigensmentioning
confidence: 99%
“…Several approaches can be used to manipulate the variable regions in order to increase the binding affinity for antigens, or tune the binding specificity, namely chain-shuffling, randomization of CDRs and induced mutations in the variable regions [ 138 , 139 ]. On the other hand, modifications in glycosylation or amino acid sequences in the constant region can modulate the Fc effector functions of antibodies, since this region is involved in ADCC and CDC [ 137 , 139 ]. Extension of the IgG half-life in serum is accomplished by engineering the Fc region particularly in modulation of its interaction with the neonatal Fc receptor (FcRn) which is associated with immunoglobulin protection from intracellular degradation [ 140 ].…”
Section: Therapeutic Antibodies Against Tn and Stn Antigensmentioning
confidence: 99%
“…Untuk meminimalkan efek imunogenik murine Mabs dalam terapi manusia, komponen imunogenik murine dihilangkan dengan peningkatan efisiensi melalui berbagai pendekatan (Rodrigues ME, et al, 2010). Imunogenisitas total Mab oleh karena itu berkurang tanpa mempengaruhi kemampuan pengenalan dari antibodi asli (Brezski RJ, Almagro JC, 2012). Antibodi yang dihasilkan dari humanisasi menjadi lebih relevan dalam pengobatan penyakit inflamasi dan kanker, dengan beberapa produk antibodi tersedia di pasaran, dan yang lainnya sedang menjalani uji klinis (O'Brien LM, et al, 2012).…”
Section: Murine Mabsunclassified